Renieramycin M Attenuates Cancer Stem Cell-like Phenotypes in H460 Lung Cancer Cells.
Cancer stem cells (CSCs) are a subpopulation of cancer cells that possess self-renewal and differentiation capacities. CSCs contribute to drug-resistance, cancer recurrence and metastasis, thus development of CSC-targeted therapeutic strategies has recently received significant attention in cancer research. In this study, the potential efficacy of renieramycin M (RM) isolated from the sponge Xestospongia species, was examined against lung CSCs.



Colony and spheroid formation assays, as well as western blotting analysis of lung CSC protein markers were employed to determine the CSC-like phenotypes of H460 lung cancer cells after treatment with RM at non-toxic concentrations.



RM treatment reduced significantly colony and spheroid formation of H460 cells. Moreover, the CSC markers CD133, CD44 and ALDH1A1 of CSC-enriched H460 cells were reduced significantly following RM treatment.



RM could be a potent anti-metastatic agent by suppressing lung CSC-like phenotypes in H460 cells.
Center for Bioactive Natural Products from Marine Organisms and Endophytic Fungi, Department of Pharmacognosy and Pharmaceutical Botany, Chulalongkorn University, Pathumwan, Bangkok, Thailand.
Natchanun
N
Sirimangkalakitti
Center for Bioactive Natural Products from Marine Organisms and Endophytic Fungi, Department of Pharmacognosy and Pharmaceutical Botany, Chulalongkorn University, Pathumwan, Bangkok, Thailand.
Supakarn
S
Chamni
Center for Bioactive Natural Products from Marine Organisms and Endophytic Fungi, Department of Pharmacognosy and Pharmaceutical Botany, Chulalongkorn University, Pathumwan, Bangkok, Thailand.
Khanit
K
Suwanborirux
Cell-Based Drug and Health Product Development Research Unit and Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, Thailand pithi_chan@yahoo.com.
Pithi
P
Chanvorachote
D000071916:AC133 Antigen / Q000378:metabolism; D000444:Aldehyde Dehydrogenase / Q000378:metabolism; D000080924:Aldehyde Dehydrogenase 1 Family; D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010641:Phenotype; D050697:Retinal Dehydrogenase; D018874:Spheroids, Cellular / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D044005:Tetrahydroisoquinolines / Q000494:pharmacology*; D047131:Xestospongia / Q000737:chemistry
D000071916:AC133 Antigen; D014408:Biomarkers, Tumor; C497483:CD44 protein, human; D018960:Hyaluronan Receptors; D044005:Tetrahydroisoquinolines; C482478:renieramycin M; D000080924:Aldehyde Dehydrogenase 1 Family; D000444:Aldehyde Dehydrogenase; C510223:ALDH1A1 protein, human; D050697:Retinal Dehydrogenase
Renieramycin M; anti-metastasis; cancer stem cell; lung cancer